Prostate Cell News Volume 4.23 | Jun 21 2013

LABORATORY RESEARCH

14-3-3 Proteins Modulate the ETS Transcription Factor ETV1 in Prostate Cancer
Scientists report that all 14-3-3 proteins, with the exception of the tumor suppressor 14-3-3σ, can bind to ETV1 in a condition manner dictated by its prominent phosphorylation site S216. S216 mutation or 14-3-3τ downregulation was sufficient to reduce ETV1 protein levels in prostate cancer cells, indicating that non-σ 14-3-3 proteins protect ETV1 from degradation. Notably, S216 mutation also decreased ETV1-dependent migration and invasion in benign prostate cells. [Cancer Res] Abstract

PSA-Responsive and PSMA-Mediated Multifunctional Liposomes for Targeted Therapy of Prostate Cancer
Scientists constructed a dual-modified liposome that incorporated prostate specific antigen (PSA)-responsive and prostate-specific membrane antigen (PSMA)-mediated liposomes and potentially offers double selectivity for prostate cancer. The folate moiety binds quickly to PSMA-positive tumors, and the PSA-responsive moiety is cleaved by PSA that was enriched in tumor tissues. [Biomaterials] Abstract

miR-221 Promotes the Development of Androgen Independence in Prostate Cancer Cells via Downregulation of HECTD2 and RAB1A
Scientists showed that stably overexpressing microRNA (miR)-221 confers androgen independent cell growth in LNCaP by rescuing LNCaP cells from growth arrest at G1 phase due to the lack of androgen. Overexpressing of miR-221 in LNCaP reduced the transcription of a subgroup of androgen-responsive genes without affecting the androgen receptor (AR) or AR-androgen integrity. [Oncogene] Abstract

Differential G Protein Subunit Expression by Prostate Cancer Cells and Their Interaction with CXCR5
Researchers examined differences in G protein expression of normal prostate and prostate cancer (PCa) cell lines (LNCaP, C4-2B, and PC3) by western blot analysis. Of the 22 G proteins studied, Galphai1-3, Gbeta1-4, Ggamma5, Ggamma7, and Ggamma10 were expressed by both normal and PCa cell lines. [Mol Cancer] Abstract | Full Article

Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis
In a transgenic adenocarcinoma mouse prostate model of prostate cancer, loss of Foxm1 decreased tumor growth and metastasis. Decreased tumorigenesis was associated with decreased tumor cell proliferation and down-regulation of genes critical for proliferation and metastasis, including Cdc25b, Cyclin B1, Plk-1, LOX and Versican. [J Biol Chem] Abstract | Full Article

A Short Peptide Derived from gN Helix Domain of FGF8b Suppressing Growth of Human Prostate Cancer Cells
The authors first designed and synthesized a gN helix domain derived short peptide based on the fibroblast growth factor (FGF)8b-FGFR structure analysis. The synthetic peptides inhibited proliferation of prostate cancer cell lines including PC-3 and DU-145 cells. [Cancer Lett] Abstract

Knockdown of Lipocalin-2 Suppresses the Growth and Invasion of Prostate Cancer Cells
Investigators identified shRNA-LCN2 to determine the role of lipocalin-2 (LCN2) in prostate-cancer cell proliferation, migration, and invasion. LCN2 protein and mRNA expression are higher in PC3 and DU145 cells than in LNCaP and 22Rv cells, and prostate cancer tissue correlated significantly with tumor differentiation and Gleason’s grade. [Prostate] Abstract

Androgen Receptor Enhances Entosis, a Non-Apoptotic Cell Death, through Modulation of Rho/ROCK Pathway in Prostate Cancer Cells
Scientists dissected the mechanism of androgen receptor (AR) signaling related to entosis incidence in prostate cancer (PCa) progression. Two stable PCa cell lines, named LNCaP-ARsi and C4-2-ARsi were established with stably transfected AR-shRNA to knockdown AR mRNA expression in LNCaP and C4-2 cells, respectively. Androgen-DHT could enhance entosis in LNCaP, C4-2 and PC3-AR9 PCa cells in a dose dependent manner. [Prostate] Abstract

CLINICAL RESEARCH

Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death
The authors hypothesized that alterations in telomere length in the primary cancer would predict risk of progression to metastasis and prostate cancer death. To test this hypothesis, they conducted a prospective cohort study of 596 surgically treated men who participated in the ongoing Health Professionals Follow-up Study. [Cancer Discov] Abstract

The Modified Glasgow Prognostic Score in Prostate Cancer: Results from a Retrospective Clinical Series of 744 Patients
The authors described the relationship between modified Glasgow Prognostic Score (mGPS) and survival in patients with prostate cancer after adjustment for other prognostic factors. Patients with mGPS of two had poorest five-year and ten-year relative survival, of 32.6% and 18.8%, respectively. [BMC Cancer]
Full Article

Searching for Prostate Cancer Stem Cells: Markers and Methods
The authors describe current methods and markers for isolating and characterizing prostate cancer stem cells, including assays for self-renewal, multipotency and resistance to therapy. [Stem Cell Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Nuclea Biotechnologies and Berkshire Medical Center Announce Research Agreement
Nuclea Biotechnologies, Inc. announced that it has signed a new research & collaboration agreement with Berkshire Medical Center which could lead to more effective treatment for prostate and breast cancer. [Nuclea Biotechnologies, Inc.] Press Release

Johnson & Johnson Announces Definitive Agreement to Acquire Aragon Pharmaceuticals, Inc.
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, Inc. The acquisition includes Aragon’s androgen receptor antagonist program. Aragon’s lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase II development for castration resistant prostate cancer. [Johnson & Johnson] Press Release

Early BPA Exposure Increases Risk of Adult Cancer
Early exposure to bisphenol A (BPA) causes an increased cancer risk in an animal model of human prostate cancer, according to University of Illinois at Chicago researcher Gail Prins. [University of Illinois at Chicago] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Gordon Research Seminar – Biomaterials & Tissue Engineering
July 27-28, 2013
Holderness, United States

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Position – Cancer Biology and Chemotherapy Resistance (Dalhousie University)

Postdoctoral Fellow – Drug Discovery/GU Oncology (Moffitt Cancer Center & Research Institute)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Research Scientist – Prostate Cancer Vaccine Development (Nuffield Department of Clinical Medicine, The Jenner Institute)

Postdoctoral Position – Castrate Resistant Prostate Cancer (Mount Sinai School)

PCUK Funded PhD Studentship – Prostate Cancer (Barts Cancer Institute, Queen Mary University of London)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.